These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 33129321)

  • 1. Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis.
    Bender TTA; Leyens J; Sellin J; Kravchenko D; Conrad R; Mücke M; Seidel MF
    Orphanet J Rare Dis; 2020 Oct; 15(1):308. PubMed ID: 33129321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological therapy for systemic vasculitis: a systematic review.
    Silva-Fernández L; Loza E; Martínez-Taboada VM; Blanco R; Rúa-Figueroa I; Pego-Reigosa JM; Muñoz-Fernández S;
    Semin Arthritis Rheum; 2014 Feb; 43(4):542-57. PubMed ID: 23978781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unmet Needs in the Pathogenesis and Treatment of Vasculitides.
    Muratore F; Pazzola G; Soriano A; Pipitone N; Croci S; Bonacini M; Boiardi L; Salvarani C
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):244-260. PubMed ID: 28895041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined prevalence of classified rare rheumatic diseases is almost double that of ankylosing spondylitis.
    Leyens J; Bender TTA; Mücke M; Stieber C; Kravchenko D; Dernbach C; Seidel MF
    Orphanet J Rare Dis; 2021 Jul; 16(1):326. PubMed ID: 34294115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
    Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methotrexate for induction of remission in refractory Crohn's disease.
    McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
    Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
    Liu ID; Willis NS; Craig JC; Hodson EM
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31749142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapy for Behcet's syndrome.
    Saenz A; Ausejo M; Shea B; Wells G; Welch V; Tugwell P
    Cochrane Database Syst Rev; 2000; 1998(2):CD001084. PubMed ID: 10796413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [ANCA-associated vasculitis].
    Holle JU
    Internist (Berl); 2015 Jan; 56(1):41-50; quiz 51-2. PubMed ID: 25502657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions for renal vasculitis in adults.
    Walters G; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2015 Sep; (9):CD003232. PubMed ID: 26400765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.
    Oaklander AL; Lunn MP; Hughes RA; van Schaik IN; Frost C; Chalk CH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD010369. PubMed ID: 28084646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions for mycosis fungoides.
    Weberschock T; Strametz R; Lorenz M; Röllig C; Bunch C; Bauer A; Schmitt J
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008946. PubMed ID: 22972128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in ANCA-Associated Vasculitis.
    Hassan RI; Gaffo AL
    Curr Rheumatol Rep; 2017 Feb; 19(2):6. PubMed ID: 28155022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review.
    Bosch X; Guilabert A; Espinosa G; Mirapeix E
    JAMA; 2007 Aug; 298(6):655-69. PubMed ID: 17684188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
    Hodson EM; Wong SC; Willis NS; Craig JC
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD003594. PubMed ID: 27726125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coronary flow reserve in systemic rheumatic diseases: a systematic review and meta-analysis.
    Erre GL; Buscetta G; Paliogiannis P; Mangoni AA; Carru C; Passiu G; Zinellu A
    Rheumatol Int; 2018 Jul; 38(7):1179-1190. PubMed ID: 29732488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WITHDRAWN: Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.
    Choy EH; Hoogendijk JE; Lecky B; Winer JB; Gordon P
    Cochrane Database Syst Rev; 2009 Oct; (4):CD003643. PubMed ID: 19821312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.
    Choy EH; Hoogendijk JE; Lecky B; Winer JB
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003643. PubMed ID: 16034905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
    Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
    Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational drugs in systemic vasculitis.
    Mirouse A; Cacoub P; Desbois AC; Comarmond C; Pagnoux C; Saadoun D
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1049-1061. PubMed ID: 28758504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.